Insider Trading Alert - MDAS, WNR, PG, VPRT And PRGO Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 26, 2013, 184 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $199.71 to $214,535,257.08.

Highlighted Stocks Traded by Insiders:

MedAssets (MDAS) - FREE Research Report

Rutherford John C who is Director at MedAssets sold 13,000 shares at $21.41 on Nov. 26, 2013. Following this transaction, the Director owned 17,832 shares meaning that the stake was reduced by 42.16% with the 13,000 share transaction.

The shares most recently traded at $21.72, up $0.31, or 1.44% since the insider transaction. Historical insider transactions for MedAssets go as follows:

  • 4-Week # shares sold: 212,000
  • 12-Week # shares sold: 216,000
  • 24-Week # shares sold: 328,527

The average volume for MedAssets has been 544,300 shares per day over the past 30 days. MedAssets has a market cap of $1.3 billion and is part of the technology sector and computer software & services industry. Shares are up 27.55% year to date as of the close of trading on Tuesday.

MedAssets, Inc., a financial and performance improvement company, provides technology-enabled products and services for hospitals, health systems, and other ancillary healthcare providers in the United States. The company has a P/E ratio of 305.6. Currently there are 11 analysts that rate MedAssets a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MDAS - FREE

TheStreet Quant Ratings rates MedAssets as a hold. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk, disappointing return on equity and weak operating cash flow. Get the full MedAssets Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Western Refining (WNR) - FREE Research Report

Weaver Scott D who is VP, Asst. Treasurer at Western Refining sold 51,692 shares at $38.21 on Nov. 26, 2013. Following this transaction, the VP, Asst. Treasurer owned 1.5 million shares meaning that the stake was reduced by 3.44% with the 51,692 share transaction.

The shares most recently traded at $39.65, up $1.44, or 3.63% since the insider transaction. Historical insider transactions for Western Refining go as follows:

  • 4-Week # shares sold: 518,659
  • 12-Week # shares sold: 749,925
  • 24-Week # shares sold: 1.3 million

The average volume for Western Refining has been 1.4 million shares per day over the past 30 days. Western Refining has a market cap of $3.1 billion and is part of the basic materials sector and energy industry. Shares are up 37.03% year to date as of the close of trading on Tuesday.

Western Refining, Inc. operates as an independent crude oil refiner and marketer of refined products. It operates in three segments: Refining, Wholesale, and Retail. The stock currently has a dividend yield of 2.28%. The company has a P/E ratio of 8.2. Currently there are 4 analysts that rate Western Refining a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WNR - FREE

TheStreet Quant Ratings rates Western Refining as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, attractive valuation levels and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Western Refining Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Procter & Gamble (PG) - FREE Research Report

Giovanni Ciserani who is GrpPres-Global Fabric&HomeCare at Procter & Gamble sold 1,860 shares at $85.55 on Nov. 26, 2013. Following this transaction, the GrpPres-Global Fabric&HomeCare owned 21,900 shares meaning that the stake was reduced by 7.83% with the 1,860 share transaction.

The shares most recently traded at $84.27, down $1.28, or 1.52% since the insider transaction. Historical insider transactions for Procter & Gamble go as follows:

  • 4-Week # shares sold: 1,965
  • 12-Week # shares sold: 3,133
  • 24-Week # shares sold: 29,279

The average volume for Procter & Gamble has been 7.8 million shares per day over the past 30 days. Procter & Gamble has a market cap of $232.2 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 24.67% year to date as of the close of trading on Tuesday.

The Procter & Gamble Company, together with its subsidiaries, manufactures and sells branded consumer packaged goods. The company operates through five segments: Beauty, Grooming, Health Care, Fabric Care and Home Care, and Baby Care and Family Care. The stock currently has a dividend yield of 2.82%. The company has a P/E ratio of 21.7. Currently there are 12 analysts that rate Procter & Gamble a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PG - FREE

TheStreet Quant Ratings rates Procter & Gamble as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Procter & Gamble Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

VistaPrint (VPRT) - FREE Research Report

Blake Katryn who is Exec VP, Global Marketing at VistaPrint sold 639 shares at $57.44 on Nov. 26, 2013. Following this transaction, the Exec VP, Global Marketing owned 16,804 shares meaning that the stake was reduced by 3.66% with the 639 share transaction.

The shares most recently traded at $57.38, down $0.06, or 0.11% since the insider transaction. Historical insider transactions for VistaPrint go as follows:

  • 4-Week # shares sold: 5,848
  • 12-Week # shares sold: 15,176
  • 24-Week # shares sold: 58,110

The average volume for VistaPrint has been 194,000 shares per day over the past 30 days. VistaPrint has a market cap of $1.9 billion and is part of the services sector and diversified services industry. Shares are up 74.95% year to date as of the close of trading on Tuesday.

Vistaprint N.V. operates as an online provider of coordinated portfolios of marketing products and services to micro businesses worldwide. The company has a P/E ratio of 60.0. Currently there is 1 analyst that rates VistaPrint a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VPRT - FREE

TheStreet Quant Ratings rates VistaPrint as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow. Get the full VistaPrint Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Perrigo Company (PRGO) - FREE Research Report

Yu Louis who is Executive VP Global Quality at Perrigo Company sold 2,292 shares at $155.51 on Nov. 26, 2013. Following this transaction, the Executive VP Global Quality owned 8,548 shares meaning that the stake was reduced by 21.14% with the 2,292 share transaction.

The shares most recently traded at $156.07, up $0.56, or 0.36% since the insider transaction. Historical insider transactions for Perrigo Company go as follows:

  • 4-Week # shares sold: 455
  • 12-Week # shares sold: 2,310
  • 24-Week # shares sold: 14,666

The average volume for Perrigo Company has been 1.0 million shares per day over the past 30 days. Perrigo Company has a market cap of $14.8 billion and is part of the health care sector and drugs industry. Shares are up 50.38% year to date as of the close of trading on Tuesday.

Perrigo Company, through its subsidiaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API). The stock currently has a dividend yield of 0.23%. The company has a P/E ratio of 33.0. Currently there are 10 analysts that rate Perrigo Company a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PRGO - FREE

TheStreet Quant Ratings rates Perrigo Company as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Perrigo Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research
null

If you liked this article you might like

New Lifetime High Reached By MedAssets (MDAS)

New Lifetime High Reached By MedAssets (MDAS)

MedAssets (MDAS) Reaches New Lifetime High Today

MedAssets (MDAS) Reaches New Lifetime High Today

MedAssets (MDAS) Stock Gains on Sale to Pamplona Capital Management

MedAssets (MDAS) Stock Gains on Sale to Pamplona Capital Management

Today MedAssets (MDAS) Hits New Lifetime High

Today MedAssets (MDAS) Hits New Lifetime High

Analysts' Actions -- Apple, Disney, Hershey and More

Analysts' Actions -- Apple, Disney, Hershey and More